Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
67.68
Dollar change
-0.71
Percentage change
-1.04
%
Index- P/E- EPS (ttm)-0.34 Insider Own13.79% Shs Outstand96.27M Perf Week-1.77%
Market Cap24.69B Forward P/E25.59 EPS next Y2.64 Insider Trans-0.01% Shs Float82.99M Perf Month15.75%
Income17.60M PEG- EPS next Q0.45 Inst Own78.11% Short Float5.56% Perf Quarter50.13%
Sales2.71B P/S9.12 EPS this Y25.11% Inst Trans1.47% Short Ratio5.11 Perf Half Y55.12%
Book/sh6.95 P/B9.74 EPS next Y34.65% ROA0.20% Short Interest4.62M Perf Year144.86%
Cash/sh3.11 P/C21.77 EPS next 5Y32.16% ROE2.83% 52W Range27.40 - 69.86 Perf YTD56.78%
Dividend Est.1.68 (2.48%) P/FCF399.28 EPS past 5Y- ROI0.91% 52W High-3.12% Beta1.52
Dividend TTM1.75 (2.59%) Quick Ratio- Sales past 5Y29.25% Gross Margin96.45% 52W Low147.01% ATR (14)1.72
Dividend Ex-DateAug 16, 2024 Current Ratio- EPS Y/Y TTM-80.99% Oper. Margin-0.76% RSI (14)70.55 Volatility2.51% 2.76%
Employees1850 Debt/Eq1.72 Sales Y/Y TTM21.75% Profit Margin0.65% Recom2.07 Target Price62.86
Option/ShortYes / Yes LT Debt/Eq1.72 EPS Q/Q-1327.15% Payout- Rel Volume1.31 Prev Close68.39
Sales Surprise-0.53% EPS Surprise14.92% Sales Q/Q23.04% EarningsNov 04 BMO Avg Volume904.00K Price67.68
SMA205.36% SMA5016.32% SMA20042.70% Trades Volume1,183,932 Change-1.04%
Date Action Analyst Rating Change Price Target Change
Sep-12-24Initiated Wells Fargo Overweight $60
May-10-24Upgrade Morgan Stanley Equal-Weight → Overweight $43 → $52
Jan-04-24Initiated TD Cowen Market Perform $38
Dec-06-23Resumed BMO Capital Markets Market Perform $36
Nov-30-23Resumed Goldman Buy $43
May-19-23Initiated Citigroup Buy $32
Jan-24-23Downgrade JP Morgan Overweight → Neutral $35 → $34
Oct-19-22Initiated Credit Suisse Neutral $27.50
Oct-17-22Initiated Jefferies Hold $30
Oct-14-22Downgrade Exane BNP Paribas Outperform → Neutral $32
Oct-29-24 03:38PM
Oct-24-24 12:00AM
Oct-21-24 03:00PM
Oct-14-24 11:38AM
Oct-07-24 08:00AM
04:22PM Loading…
Sep-30-24 04:22PM
04:01PM
09:30AM
08:44AM
07:53AM
07:46AM
07:00AM
06:55AM
06:13AM
Sep-27-24 01:44PM
10:00AM Loading…
10:00AM
07:00AM
Sep-26-24 05:00PM
Sep-16-24 09:05PM
Sep-11-24 07:55AM
Sep-06-24 03:08PM
Sep-03-24 04:20PM
04:05PM
Aug-23-24 05:46AM
Aug-22-24 09:00AM
Aug-15-24 01:00AM
Aug-06-24 03:39PM
08:00AM
Jul-18-24 12:06AM
Jul-16-24 04:49AM
08:00AM Loading…
Jul-10-24 08:00AM
Jul-04-24 12:00PM
Jun-28-24 08:00AM
07:55AM
Jun-17-24 09:30AM
Jun-08-24 05:30PM
May-29-24 08:00AM
May-22-24 08:07AM
May-08-24 12:54PM
09:25AM
08:00AM
May-02-24 01:00PM
May-01-24 10:01AM
Apr-24-24 12:10PM
Apr-17-24 09:00AM
Apr-15-24 09:02AM
Apr-04-24 08:00AM
Apr-03-24 08:00AM
Mar-29-24 01:13AM
Mar-24-24 11:00AM
Mar-07-24 10:05AM
Mar-04-24 09:40AM
Mar-01-24 11:36PM
Feb-29-24 05:25PM
09:19AM
Feb-28-24 09:10PM
Feb-27-24 08:50AM
Feb-26-24 09:11AM
06:25AM
Feb-21-24 09:06AM
Feb-20-24 01:46PM
Feb-19-24 01:16PM
Feb-14-24 08:00AM
Feb-13-24 09:25AM
08:00AM
Feb-06-24 10:00AM
Feb-05-24 10:27AM
Jan-24-24 06:32PM
Jan-23-24 04:58PM
08:47AM
08:00AM
Jan-18-24 05:46PM
Jan-16-24 03:48PM
09:00AM
Jan-11-24 08:00AM
Jan-10-24 08:00AM
Dec-27-23 07:47AM
Dec-18-23 01:24PM
Dec-15-23 07:55AM
Dec-01-23 06:06AM
Nov-21-23 08:00AM
Nov-07-23 03:20PM
08:00AM
05:30AM
Nov-06-23 08:33AM
Nov-02-23 07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-25-23 01:33PM
Sep-20-23 12:13AM
Sep-19-23 09:00AM
Sep-13-23 08:30AM
Sep-05-23 12:31PM
08:00AM
Aug-28-23 12:00PM
Aug-12-23 08:04AM
Aug-09-23 08:40AM
Aug-08-23 08:00AM
Jul-31-23 01:39PM
Jul-27-23 04:05PM
TPG, Inc. operates as a global, diversified alternative asset management firm. It invests across five multi-product platforms: Capital, Growth, Impact, Real Estate, and Market Solutions. The firm aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. The company was founded by Jim Coulter and David Bonderman in 1992 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MESSEMER DEBORAH M.DirectorJul 17 '24Sale46.554,089190,33217,536Jul 17 05:37 PM
MESSEMER DEBORAH M.DirectorFeb 28 '24Sale43.976,390280,98018,033Mar 01 05:14 PM
Vazquez-Ubarri AniluChief Operating OfficerFeb 27 '24Option Exercise0.00101,9370435,648Feb 29 07:23 PM
Vazquez-Ubarri AniluChief Operating OfficerFeb 29 '24Sale41.64101,9374,244,657333,711Feb 29 07:23 PM
WINKELRIED JONChief Executive OfficerFeb 27 '24Option Exercise0.001,000,00004,326,460Feb 29 07:01 PM
WINKELRIED JONChief Executive OfficerFeb 29 '24Sale41.641,000,00041,640,0003,326,460Feb 29 07:01 PM
WINKELRIED JONChief Executive OfficerFeb 29 '24Sale41.6450,8482,117,3110Feb 29 07:01 PM
Weingart JackChief Financial OfficerFeb 27 '24Option Exercise0.00308,46801,084,450Feb 29 06:57 PM
Weingart JackChief Financial OfficerFeb 29 '24Sale41.64308,46812,844,608775,982Feb 29 06:57 PM
Trujillo DavidDirectorFeb 27 '24Option Exercise0.00397,5100580,029Feb 29 06:45 PM
Trujillo DavidDirectorFeb 29 '24Sale41.64397,51016,552,316182,519Feb 29 06:45 PM
Sisitsky Todd BenjaminPresidentFeb 27 '24Option Exercise0.00660,15101,172,917Feb 29 06:43 PM
Sisitsky Todd BenjaminPresidentFeb 29 '24Sale41.64660,15127,488,688512,766Feb 29 06:43 PM
Sisitsky Todd BenjaminPresidentFeb 29 '24Sale41.6452,8072,198,883396,982Feb 29 06:43 PM
Sarvananthan GanendranDirectorFeb 27 '24Option Exercise0.00162,7070215,093Feb 29 06:41 PM
Sarvananthan GanendranDirectorFeb 29 '24Sale41.64172,7057,191,43642,388Feb 29 06:41 PM
Rhodes Jeffrey K.DirectorFeb 27 '24Option Exercise0.00408,6750585,167Feb 29 06:38 PM
Rhodes Jeffrey K.DirectorFeb 29 '24Sale41.64408,67517,017,227176,492Feb 29 06:38 PM
Raj NehalDirectorFeb 27 '24Option Exercise0.00250,8580800,570Feb 29 06:36 PM
Raj NehalDirectorFeb 29 '24Sale41.64250,85810,445,727549,712Feb 29 06:36 PM
Harris JoannChief Compliance OfficerFeb 27 '24Option Exercise0.0023,745023,745Feb 29 06:33 PM
Harris JoannChief Compliance OfficerFeb 29 '24Sale41.6423,745988,7420Feb 29 06:33 PM
Harris JoannChief Compliance OfficerFeb 29 '24Sale41.641,73972,41222,860Feb 29 06:33 PM
Davis Kelvin L.DirectorFeb 27 '24Option Exercise0.00822,01701,666,601Feb 29 06:29 PM
Davis Kelvin L.DirectorFeb 29 '24Sale41.64822,01734,228,788844,584Feb 29 06:29 PM
Davidson MartinChief Accounting OfficerFeb 27 '24Option Exercise0.0039,317070,308Feb 29 06:26 PM
Davidson MartinChief Accounting OfficerFeb 29 '24Sale41.6439,3171,637,16030,991Feb 29 06:26 PM
COULTER JAMES GExecutive ChairmanFeb 27 '24Option Exercise0.001,250,00001,266,949Feb 29 06:24 PM
COULTER JAMES GExecutive ChairmanFeb 29 '24Sale41.641,334,74655,578,8230Feb 29 06:24 PM
COULTER JAMES GExecutive ChairmanFeb 29 '24Sale41.6416,949705,756386,936Feb 29 06:24 PM
COSLET JONATHAN JDirectorFeb 27 '24Option Exercise0.001,000,00001,000,000Feb 29 06:22 PM
COSLET JONATHAN JDirectorFeb 29 '24Sale41.641,000,00041,640,0000Feb 29 06:22 PM
Chorengel MayaDirectorFeb 27 '24Option Exercise0.0069,2980131,919Feb 29 06:20 PM
Chorengel MayaDirectorFeb 29 '24Sale41.6474,7733,113,54857,146Feb 29 06:20 PM
BONDERMAN DAVIDDirectorFeb 27 '24Option Exercise0.001,500,00001,516,949Feb 29 06:18 PM
BONDERMAN DAVIDDirectorFeb 29 '24Sale41.641,584,74665,988,8230Feb 29 06:18 PM
BONDERMAN DAVIDDirectorFeb 29 '24Sale41.6416,949705,75637,967Feb 29 06:18 PM
Berenson BradfordGeneral CounselFeb 27 '24Option Exercise0.0090,8950287,147Feb 29 06:15 PM
Berenson BradfordGeneral CounselFeb 29 '24Sale41.6490,8953,784,868196,252Feb 29 06:15 PM
Last Close
Oct 31 04:00PM ET
2.56
Dollar change
-0.09
Percentage change
-3.22
%
ALLO Allogene Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.61 Insider Own33.98% Shs Outstand167.13M Perf Week0.59%
Market Cap534.28M Forward P/E- EPS next Y-1.46 Insider Trans2.44% Shs Float138.06M Perf Month0.99%
Income-278.45M PEG- EPS next Q-0.33 Inst Own66.85% Short Float28.48% Perf Quarter-0.58%
Sales0.09M P/S5936.40 EPS this Y33.75% Inst Trans28.36% Short Ratio20.93 Perf Half Y-13.97%
Book/sh2.46 P/B1.04 EPS next Y-5.43% ROA-39.28% Short Interest39.32M Perf Year-9.40%
Cash/sh2.13 P/C1.20 EPS next 5Y1.00% ROE-48.94% 52W Range2.01 - 5.78 Perf YTD-20.40%
Dividend Est.- P/FCF- EPS past 5Y22.18% ROI-46.25% 52W High-55.76% Beta0.83
Dividend TTM- Quick Ratio12.25 Sales past 5Y-27.79% Gross Margin-16467.44% 52W Low27.11% ATR (14)0.20
Dividend Ex-Date- Current Ratio12.25 EPS Y/Y TTM34.36% Oper. Margin-314866.28% RSI (14)45.66 Volatility10.48% 6.96%
Employees233 Debt/Eq0.18 Sales Y/Y TTM-24.70% Profit Margin-323780.23% Recom1.53 Target Price9.26
Option/ShortYes / Yes LT Debt/Eq0.17 EPS Q/Q34.27% Payout- Rel Volume1.18 Prev Close2.64
Sales Surprise-99.92% EPS Surprise0.00% Sales Q/Q-100.00% EarningsNov 07 AMC Avg Volume1.88M Price2.56
SMA20-4.80% SMA50-5.02% SMA200-19.80% Trades Volume2,208,002 Change-3.22%
Date Action Analyst Rating Change Price Target Change
Aug-08-24Resumed Oppenheimer Outperform $13 → $11
May-31-24Initiated Piper Sandler Overweight $11
Jan-05-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jan-05-24Downgrade Guggenheim Buy → Neutral
Dec-08-23Initiated Citigroup Buy $7
Dec-08-23Initiated Citigroup Buy
Jun-26-23Resumed Oppenheimer Outperform $28
Mar-21-23Initiated Bernstein Mkt Perform $6
Jan-24-23Upgrade JP Morgan Neutral → Overweight $20 → $11
Jan-06-23Upgrade Robert W. Baird Neutral → Outperform $12
Today 10:01AM
Oct-30-24 08:30AM
Oct-29-24 08:30AM
Oct-22-24 04:05PM
Oct-03-24 07:19AM
08:30AM Loading…
Sep-30-24 08:30AM
Sep-26-24 08:30AM
Sep-14-24 05:39PM
Sep-06-24 11:31AM
Aug-08-24 09:50AM
08:30AM
06:00AM
Aug-07-24 04:10PM
04:02PM
Jul-31-24 08:30AM
08:30AM Loading…
Jul-01-24 08:30AM
Jun-27-24 10:13AM
Jun-26-24 04:36PM
Jun-20-24 08:30AM
Jun-12-24 11:30AM
May-29-24 08:55AM
May-28-24 04:05PM
May-23-24 08:30AM
May-21-24 01:56PM
08:16AM
May-16-24 08:13AM
May-14-24 12:56PM
09:14AM
08:21AM
03:06AM
08:55PM Loading…
May-13-24 08:55PM
05:36PM
05:10PM
04:47PM
04:17PM
04:14PM
04:01PM
May-06-24 08:30AM
Apr-26-24 10:32AM
08:30AM
Apr-24-24 10:01AM
Apr-11-24 02:45PM
Apr-09-24 08:30AM
Apr-08-24 08:46AM
Mar-16-24 04:35PM
Mar-15-24 09:32AM
07:04AM
Mar-14-24 08:55PM
05:34PM
05:15PM
04:15PM
04:05PM
Mar-13-24 12:15PM
Mar-12-24 08:50AM
08:30AM
Mar-05-24 09:55AM
08:30AM
Feb-28-24 08:30AM
Feb-16-24 08:30AM
Jan-16-24 04:05PM
Jan-12-24 08:34AM
Jan-05-24 12:52PM
08:25AM
08:13AM
Jan-04-24 04:15PM
04:05PM
11:05AM
Jan-03-24 04:05PM
Dec-09-23 12:00PM
Dec-01-23 08:30AM
Nov-24-23 06:40AM
Nov-10-23 12:00PM
Nov-03-23 12:15PM
12:00PM
12:00PM
10:15AM
Nov-02-23 07:33PM
04:12PM
04:02PM
09:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-16-23 09:26AM
08:30AM
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
Jun-09-23 06:25PM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.OfficerOct 21 '24Proposed Sale2.8436,404103,501Oct 21 04:05 PM
Douglas Earl MartinOfficerAug 21 '24Proposed Sale2.7928,31078,844Aug 21 04:18 PM
MESSEMER DEBORAH M.DirectorJun 18 '24Sale2.2818,64142,488166,765Jun 20 04:31 PM
Humer Franz BDirectorMay 30 '24Sale2.3411,20026,181255,253Jun 03 04:09 PM
Belldegrun ArieDirectorMay 16 '24Buy2.901,724,1374,999,9971,724,137May 20 09:33 PM
Parker Geoffrey M.CHIEF FINANCIAL OFFICERJan 30 '24Buy3.60190683819,590Mar 06 09:52 PM
MESSEMER DEBORAH M.DirectorDec 18 '23Sale2.7018,64050,31762,456Dec 20 04:26 PM